Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #105 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Trident Lifeline Limited (this stock) | 437 | — | — | 38.7% | — | 92 | — | 87 |
Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet. EBITDA = PBT + interest + depreciation.
Jun 2026 quarterly revenue is Rs 27 Cr, up 41.4% YoY.
Jun 2026 quarterly net profit is Rs 5 Cr, up 44.4% YoY.
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 27 | 7 | 5 | ₹ |
| Dec. 31, 2025 | 24 | 6 | 4 | ₹ |
| June 30, 2025 | 19 | 5 | 3 | ₹ |
| June 30, 2024 | 15 | 4 | 3 | ₹ |
| June 30, 2023 | 9 | 2 | 1 | ₹ |
| Dec. 31, 2022 | 9 | 2 | 2 | ₹ |
| Indicator | Jun 26 | Dec 25 | Jun 25 | Jun 24 | Jun 23 | Dec 22 |
|---|---|---|---|---|---|---|
| Total income (before exceptional items) | 27 | 25 | 19 | 15 | 9 | 10 |
| Operating revenue | 27 | 24 | 19 | 15 | 9 | 9 |
| Other income | 1 | 1 | 1 | 0 | 0 | 0 |
| Operating expenses | 20 | 17 | 14 | 11 | 7 | 7 |
| Operating profit | 7 | 6 | 5 | 4 | 2 | 2 |
| Operating profit margin | 26.9% | 26.5% | 26.2% | 27.7% | 20.4% | 21.0% |
| Depreciation | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 |
| Exceptional items, gain / (loss) | — | — | — | — | — | — |
| Profit before tax | 7 | 6 | 5 | 4 | 2 | 2 |
| Tax | 2 | 2 | 1 | 1 | 0 | 0 |
| Net profit | 5 | 4 | 3 | 3 | 1 | 2 |
| EPS | — | — | — | — | — | — |
| Net profit (TTM) | 16 | 12 | 10 | — | — | — |
| EPS (TTM) | — | — | — | — | — | — |
Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.
Data unavailable (annual figures are only available from the NSE iXBRL feed's coverage period).
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 5 | -37 | 34 | 36 | -32 |
| March 31, 2025 | -3 | -8 | 7 | 5 | -9 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 159 | — | — | — | — | 110 | 52 | 4 | 18 | 23 |
| March 31, 2025 | 98 | — | — | — | — | 69 | 25 | 2 | 8 | 17 |
Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.
